ValuEngine downgraded shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) from a sell rating to a strong sell rating in a research report released on Monday morning.
Several other analysts also recently weighed in on the company. Leerink Swann raised Achillion Pharmaceuticals from a market perform rating to an outperform rating and boosted their target price for the company from $4.00 to $6.00 in a report on Thursday, May 18th. Zacks Investment Research downgraded Achillion Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, July 11th. BidaskClub downgraded Achillion Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, July 25th. Chardan Capital reduced their target price on Achillion Pharmaceuticals from $5.00 to $4.00 and set a neutral rating for the company in a report on Wednesday, August 9th. Finally, Maxim Group set a $7.00 target price on Achillion Pharmaceuticals and gave the company a buy rating in a report on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of $8.13.
Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 3.825 on Monday. The stock has a 50 day moving average price of $4.59 and a 200-day moving average price of $4.21. Achillion Pharmaceuticals has a one year low of $3.15 and a one year high of $9.19. The firm’s market capitalization is $523.11 million.
Achillion Pharmaceuticals (NASDAQ:ACHN) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). During the same period in the previous year, the company earned ($0.14) earnings per share. On average, analysts predict that Achillion Pharmaceuticals will post ($0.66) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Achillion Pharmaceuticals, Inc. (ACHN) Lowered to Strong Sell at ValuEngine” was published by Ticker Report and is the property of of Ticker Report. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/2886229/achillion-pharmaceuticals-inc-achn-lowered-to-strong-sell-at-valuengine.html.
Institutional investors and hedge funds have recently bought and sold shares of the business. Deschutes Portfolio Strategy LLC raised its stake in Achillion Pharmaceuticals by 358.6% during the 2nd quarter. Deschutes Portfolio Strategy LLC now owns 116,630 shares of the biopharmaceutical company’s stock valued at $535,000 after acquiring an additional 91,200 shares during the last quarter. Highbridge Capital Management LLC purchased a new stake in Achillion Pharmaceuticals during the 1st quarter valued at approximately $149,000. Dimensional Fund Advisors LP raised its stake in Achillion Pharmaceuticals by 51.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 613,006 shares of the biopharmaceutical company’s stock valued at $2,581,000 after acquiring an additional 207,204 shares during the last quarter. Wells Fargo & Company MN raised its stake in Achillion Pharmaceuticals by 11.9% during the 1st quarter. Wells Fargo & Company MN now owns 215,820 shares of the biopharmaceutical company’s stock valued at $908,000 after acquiring an additional 22,931 shares during the last quarter. Finally, Credit Suisse AG raised its stake in Achillion Pharmaceuticals by 106.0% during the 1st quarter. Credit Suisse AG now owns 237,819 shares of the biopharmaceutical company’s stock valued at $1,002,000 after acquiring an additional 122,361 shares during the last quarter. 74.12% of the stock is owned by hedge funds and other institutional investors.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.